子宮筋腫核出術の2030年までの市場予測：製品タイプ、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の子宮筋腫核出術市場は2023年に7億5,659万米ドルを占め、2030年には15億8,073万米ドルに達すると予測され、予測期間中に11.1％のCAGRで成長します。

子宮筋腫核出術は、子宮筋腫として知られる非がん性の増殖を子宮の筋壁から除去することを目的とした外科的処置です。これは、子宮摘出を避けたい女性や妊孕性を維持したい女性にとって実行可能な選択肢です。さらに、開腹手術、腹腔鏡手術、ロボット支援手術など、多くの手技を用いてこの手術を行うことができます。

Society for Women's Health Researchの報告によると、米国では15～50歳の女性の約2,600万人に子宮筋腫があります。

増加する子宮筋腫の有病率

子宮筋腫は一般的な良性腫瘍であり、特に生殖期にかなりの数の女性に影響を及ぼしています。例えば、イリノイ州公衆衛生局によると、出産適齢期の女性の約77％が子宮筋腫の可能性があるとされています。したがって、子宮筋腫の診断を受ける女性が増えるにつれ、その結果生じる症状を管理するための効率的な治療ソリューションの必要性が高まっています。さらに、腹腔鏡やロボット支援手術などの低侵襲技術が子宮筋腫摘出術で人気を集めています。このような子宮筋腫の有病率の増加は、子宮筋腫核出術の需要を煽り、市場の拡大を推進しています。

妊孕性への懸念

子宮筋腫核出術は、子宮筋腫を摘出することで生殖能力を保護することを目的としていても、生殖能力に影響を与える可能性があります。特に子宮筋腫が多発したり大きくなったりした場合の手術は、子宮に瘢痕や変化をもたらす可能性があり、生殖能力に影響を与える可能性があります。将来子供を持ちたいと考えている女性は、子宮筋腫核出術後の生殖能力に問題が生じるのではないかという懸念に影響されます。これは治療に関する意思決定プロセスに影響し、市場の拡大を制限する可能性さえあります。

低侵襲手術に対する需要の高まり

回復時間の短縮、傷跡の軽減、日常生活への早期復帰を理由に、腹腔鏡やロボット支援による子宮筋腫核出術のような低侵襲手技を好む患者が増加しています。このような嗜好の高まりは、特に妊孕性の温存を求める女性の間で、効果的でありながら侵襲の少ない治療法に対する要望と一致しています。さらに、このような高度な手技を提供するヘルスケアプロバイダーは、子宮筋腫核出術を求めるより多くの患者を引き付けることができ、低侵襲な選択肢に対する需要の高まりに対応し、市場を拡大する可能性があります。

手術以外の選択肢

子宮動脈塞栓術（UAE）や集束超音波手術（FUS）のような高度な非外科的治療は、手術をせずに子宮筋腫を治療する効果的な選択肢を提供します。これらの非外科的治療の利用可能性と成功率の増加は、従来の子宮筋腫核出術市場に課題を提起し、外科的処置の需要を潜在的に減少させ、外科的介入を伴わない子宮筋腫管理のための説得力のある代替手段を提供することにより、市場の成長に影響を与えます。

COVID-19の影響

COVID-19の流行は女性のヘルスケアと子宮筋腫核出術市場に深刻な影響を与えました。COVID-19の流行は、診断と治療の遅れ、医療現場における緊急性のない治療の延期を引き起こしました。また、サプライチェーンの中断により、子宮筋腫核出術に必要な医療用品の入手が困難になった。さらに、病院はCOVID-19治療のために資金を流用し、緊急でない医療活動への集中に影響を与えました。その結果、COVID-19は子宮筋腫核出術市場の成長を制限しました。

予測期間中、腹腔鏡下子宮筋腫核出術部門が最大となる見込み

腹腔鏡下子宮筋腫核出術セグメントが最大のシェアを占めると推定されます。腹腔鏡下子宮筋腫核出術は、子宮筋腫を摘出するための低侵襲な外科的処置を伴う。この手技は、小さな切開を利用し、そこから特殊な器具と腹腔鏡を挿入し、子宮を拡大して見ることができます。さらに、入院期間の短縮、回復の早さ、術後合併症の減少といった利点もあります。低侵襲なオプションに対する患者の嗜好の高まりと腹腔鏡技術の進歩により、このセグメントは子宮筋腫の治療法として引き続き支持を集めています。

予測期間中、病院・診療所セグメントのCAGRが最も高くなると予想される

病院・診療所セグメントは、予測期間中に有利な成長を遂げると予測されています。高度な医療インフラと熟練した医療専門家を備えた病院・クリニックは、子宮筋腫のさまざまな治療法を求める患者に対応しています。総合的な診断評価、外科的専門知識、術後ケアを提供し、腹腔鏡、ロボット支援、開腹筋腫核出術など多様な外科的アプローチで患者のニーズに対応しています。さらに、病院やクリニックは専門的なケアを提供する上で極めて重要な役割を担っており、子宮筋腫核出術による子宮筋腫の利用しやすく包括的な管理に大きく貢献しています。

最大のシェアを占める地域

アジア太平洋地域は、子宮障害に悩む女性の増加と新興経済諸国の主要企業による手術装置産業への投資の増加により、推定期間中最大の市場シェアを占めました。中国と日本は、子宮筋腫核出術の市場拡大において重要な役割を果たしています。外科医や婦人科医を含む高度に熟練した医療従事者の供給や、研究目的での遺伝子チップのような技術的に洗練された医療技術に対するニーズの高まりが、この成長の主な理由です。

CAGRが最も高い地域：

北米は、子宮筋腫の有病率の上昇と子宮筋腫核出術の技術的進歩により、予測期間中に有益な成長を示すことが期待されています。米国女性健康局が2021年2月に更新したデータによると、女性の約20％～80％が50歳になるまでに子宮筋腫を発症すると推定されています。子宮筋腫を発症する可能性が高いのは、40代から50代前半の女性です。すべての子宮筋腫に症状が出るわけではありませんが、子宮筋腫がある人は、子宮筋腫との生活に困難を感じることがよくあります。このように、米国では子宮筋腫の負担が大きいため、市場の成長が期待されています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の子宮筋腫核出術市場：製品別

• 腹腔鏡パワーモルセレーター
• 腹腔鏡シーラー
• ハーモニックメス
• その他の製品

第6章 世界の子宮筋腫核出術市場：タイプ別

• 腹部筋腫切除術
• 腹腔鏡下筋腫切除術
• 子宮鏡下筋腫切除術
• ロボット筋腫切除術

第7章 世界の筋腫核出術市場：エンドユーザー別

• 外来手術センター
• 病院・クリニック
• その他のエンドユーザー

第8章 世界の子宮筋腫核出術市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Medtronic
• Conmed Corporation
• Stryker Corporation
• Insightec
• Hologic, Inc
• Cooper Surgical Inc
• Intuitive Surgical
• Braun Melsungen AG
• Minerva Surgical Inc
• Johnson And Johnson Services Inc.
• Karl Storz
• Boston Scientific Corporation
• General Electric Company
• F. Hoffmann-La Roche Ltd
• Richard Wolf Medical Instruments
• Siemens
• Bayer
• AbbVie Inc.
• Halt Medical, Inc.

List of Tables

• Table 1 Global Myomectomy Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 4 Global Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 5 Global Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 6 Global Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 7 Global Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 8 Global Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 9 Global Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 10 Global Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 11 Global Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 12 Global Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 13 Global Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 14 Global Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 15 Global Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 16 North America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
• Table 17 North America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 18 North America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 19 North America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 20 North America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 21 North America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 22 North America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 23 North America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 24 North America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 25 North America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 26 North America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 27 North America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 28 North America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 29 North America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 30 North America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 31 Europe Myomectomy Market Outlook, By Country (2021-2030) ($MN)
• Table 32 Europe Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 33 Europe Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 34 Europe Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 35 Europe Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 36 Europe Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 37 Europe Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 38 Europe Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 39 Europe Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 40 Europe Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 41 Europe Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 42 Europe Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 43 Europe Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 44 Europe Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 45 Europe Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 46 Asia Pacific Myomectomy Market Outlook, By Country (2021-2030) ($MN)
• Table 47 Asia Pacific Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 48 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 49 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 50 Asia Pacific Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 51 Asia Pacific Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 52 Asia Pacific Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 53 Asia Pacific Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 54 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 55 Asia Pacific Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 56 Asia Pacific Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 57 Asia Pacific Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 58 Asia Pacific Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 59 Asia Pacific Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 60 Asia Pacific Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 61 South America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
• Table 62 South America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 63 South America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 64 South America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 65 South America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 66 South America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 67 South America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 68 South America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 69 South America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 70 South America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 71 South America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 72 South America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 73 South America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 74 South America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 75 South America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 76 Middle East & Africa Myomectomy Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Middle East & Africa Myomectomy Market Outlook, By Product (2021-2030) ($MN)
• Table 78 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
• Table 79 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
• Table 80 Middle East & Africa Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
• Table 81 Middle East & Africa Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
• Table 82 Middle East & Africa Myomectomy Market Outlook, By Type (2021-2030) ($MN)
• Table 83 Middle East & Africa Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
• Table 84 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
• Table 85 Middle East & Africa Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
• Table 86 Middle East & Africa Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
• Table 87 Middle East & Africa Myomectomy Market Outlook, By End User (2021-2030) ($MN)
• Table 88 Middle East & Africa Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 89 Middle East & Africa Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 90 Middle East & Africa Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Myomectomy Market is accounted for $756.59 million in 2023 and is expected to reach $1580.73 million by 2030 growing at a CAGR of 11.1% during the forecast period. A myomectomy is a surgical procedure aimed at removing noncancerous growths known as uterine fibroids from the muscular wall of the uterus. It is a viable alternative for women who want to avoid a hysterectomy or maintain their fertility. Furthermore, a number of techniques, such as open surgery, laparoscopy, and robotic-assisted surgery, can be used to carry out this procedure.

According to the Society for Women's Health Research report, in the U.S. approximately 26 million women ages 15-50 have uterine fibroids.

Market Dynamics:

Driver:

Growing prevalence of uterine fibroids

Uterine fibroids are common benign tumours affecting a substantial number of women, particularly during their reproductive years. For instance, according to the Illinois Department of Public Health, around 77% of women of childbearing age may have uterine fibroids. Therefore, as more women have uterine fibroids diagnoses, there is a growing need for efficient treatment solutions to manage the resulting symptoms. Furthermore, minimally invasive techniques such as laparoscopy and robotic-assisted surgery are gaining popularity in myomectomy. This growing prevalence of uterine fibroids fuels the demand for myomectomy procedures, propelling the market's expansion

Restraint:

Fertility concerns

Myomectomy has the potential to affect fertility ability, even if the aim is to protect fertility by removing uterine fibroids. The surgical procedure, especially if multiple or large fibroids are removed, might lead to scarring or alterations in the uterus, potentially affecting reproductive capabilities. Women who wish to have children in the future are influenced by their concern about possible issues with their fertility after a myomectomy. This affects their decision-making process regarding treatment and may even restrict the market's expansion.

Opportunity:

Rising demand for minimally invasive procedures

Patients increasingly favour minimally invasive techniques like laparoscopic or robotic-assisted myomectomy due to reduced recovery times, less scarring, and a quicker return to daily activities. This growing preference aligns with the desire for effective yet less invasive treatments, especially among women seeking fertility preservation. Furthermore, healthcare providers offering these advanced procedures can attract more patients seeking myomectomy, addressing the rising demand for minimally invasive options and potentially expanding the market.

Threat:

Non-surgical alternatives

Advanced non-surgical treatments like uterine artery embolisation (UAE) or focused ultrasound surgery (FUS) offer effective options for treating uterine fibroids without surgery. The availability and increasing success rates of these non-surgical treatments pose a challenge to the traditional myomectomy market, potentially reducing the demand for surgical procedures and impacting the market's growth by offering compelling alternatives for fibroid management without surgical interventions.

COVID-19 Impact

The COVID-19 epidemic severely impacted women's healthcare and the market for myomectomy procedures. It caused delays in diagnosis and treatment, as well as the postponement of non-urgent treatments in the medical field. Also, interruptions in the supply chain impacted the accessibility of medical supplies required for myomectomy operations. In addition, hospitals diverted funds for COVID-19 therapy, which affected the focus on non-urgent medical operations. Consequently, COVID-19 limited the growth of the myomectomy market.

The laparoscopic myomectomy segment is expected to be the largest during the forecast period

The laparoscopic myomectomy segment is estimated to hold the largest share. Laparoscopic myomectomy involves a minimally invasive surgical procedure to remove uterine fibroids. This technique utilizes small incisions through which specialized instruments and a laparoscope are inserted, providing a magnified view of the uterus. Moreover, it offers benefits like shorter hospital stays, faster recuperation, and reduced postoperative complications. With increasing patient preference for minimally invasive options and advancements in laparoscopic techniques, this segment continues to gain traction as a preferred method for treating uterine fibroids.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to have lucrative growth during the forecast period. Hospitals and clinics equipped with advanced medical infrastructure and skilled healthcare professionals cater to patients seeking various treatment options for uterine fibroids. They offer comprehensive diagnostic evaluations, surgical expertise, and postoperative care, addressing patient needs with diverse surgical approaches such as laparoscopic, robotic-assisted, or open myomectomy procedures. In addition, hospitals and clinics play a pivotal role in delivering specialised care, contributing significantly to the accessible and comprehensive management of uterine fibroids through myomectomy.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the increasing number of women suffering from uterine disorders and the rising investment in the surgical device industry by key players in developing economies. China and Japan have played a significant role in the market expansion for myomectomy procedures. The supply of highly skilled medical personnel, including surgeons and gynaecologists, as well as the rising need for technologically sophisticated medical technologies, such as gene chips, for research purposes, are the main reasons for this growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures. According to the data updated by the United States Office on Women's Health in February 2021, it was estimated that about 20 percent to 80 percent of women developed fibroids by the time they reached age 50. Women in their 40s and early 50s are most likely to develop uterine fibroids. While not all fibroids cause symptoms, those who do frequently find living with their fibroids to be difficult. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.

Key players in the market:

Some of the key players in the Myomectomy Market include Medtronic, Conmed Corporation, Stryker Corporation, Insightec, Hologic, Inc, Cooper Surgical Inc, Intuitive Surgical, Braun Melsungen AG, Minerva Surgical Inc, Johnson And Johnson Services Inc., Karl Storz, Boston Scientific Corporation, General Electric Company, F. Hoffmann-La Roche Ltd, Richard Wolf Medical Instruments, Siemens, Bayer, AbbVie Inc. and Halt Medical, Inc.

Key Developments:

In November 2022, Olympus announced the market launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's pneumoLiner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.

In April 2022, Ethicon, part of Johnson & Johnson MedTech, launched the ENSEAL X1 Straight Jaw Tissue Sealer. The ENSEAL X1 Straight Jaw is indicated for use in open and laparoscopic general, gynecological, and urologic procedures.

Products Covered:

• Laparoscopic Power Morcellators
• Laparoscopic Sealer
• Harmonic Scalpel
• Other Products

Types Covered:

• Abdominal Myomectomy
• Laparoscopic Myomectomy
• Hysteroscopic Myomectomy
• Robotic Myomectomy

End Users Covered:

• Ambulatory Surgical Centers
• Hospitals & Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Myomectomy Market, By Product

• 5.1 Introduction
• 5.2 Laparoscopic Power Morcellators
• 5.3 Laparoscopic Sealer
• 5.4 Harmonic Scalpel
• 5.5 Other Products

6 Global Myomectomy Market, By Type

• 6.1 Introduction
• 6.2 Abdominal Myomectomy
• 6.3 Laparoscopic Myomectomy
• 6.4 Hysteroscopic Myomectomy
• 6.5 Robotic Myomectomy

7 Global Myomectomy Market, By End User

• 7.1 Introduction
• 7.2 Ambulatory Surgical Centers
• 7.3 Hospitals & Clinics
• 7.4 Other End Users

8 Global Myomectomy Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Medtronic
• 10.2 Conmed Corporation
• 10.3 Stryker Corporation
• 10.4 Insightec
• 10.5 Hologic, Inc
• 10.6 Cooper Surgical Inc
• 10.7 Intuitive Surgical
• 10.8 Braun Melsungen AG
• 10.9 Minerva Surgical Inc
• 10.10 Johnson And Johnson Services Inc.
• 10.11 Karl Storz
• 10.12 Boston Scientific Corporation
• 10.13 General Electric Company
• 10.14 F. Hoffmann-La Roche Ltd
• 10.15 Richard Wolf Medical Instruments
• 10.16 Siemens
• 10.17 Bayer
• 10.18 AbbVie Inc.
• 10.19 Halt Medical, Inc.